{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994554110464.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood.v97.5.1202"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/97/5/1202/1671769/1202.pdf"}},{"identifier":{"@type":"PMID","@value":"11222361"}},{"identifier":{"@type":"NAID","@value":"30022492925"}}],"dc:title":[{"@value":"Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p>Advances in chemotherapy have led to a favorable long-term prognosis in approximately 50% of patients with aggressive non-Hodgkin lymphoma (NHL). However, the remaining patients do not enjoy such prolonged survival after standard treatment. New prognostic factors are needed to define this poor-prognosis group and to plan an appropriate treatment strategy. It has been reported that serum nm23-H1 protein may be a new prognostic factor for aggressive NHL. In the present study involving multiple institutions and a large number of patients, the level of nm23-H1 protein was compared among different types of lymphoma; it was lowest for indolent lymphoma, followed by aggressive lymphoma and then highly aggressive lymphoma. In addition, patients with aggressive NHL and higher nm23-H1 levels had worse overall and progression-free survival rates than those with lower nm23-H1 levels. The nm23-H1 level was also compared between patients with diffuse large B-cell lymphoma and patients with peripheral T-cell lymphoma. The results suggest that the level of nm23-H1 could serve as a prognostic factor in both groups. Moreover, the prognosis of lymphoma patients could be ascertained even more precisely by combining soluble interleukin-2 receptor or soluble CD44 and nm23-H1 levels. A multivariate analysis confirmed that the nm23-H1 level is an independent and important prognostic factor in aggressive NHL. Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994554110464","@type":"Researcher","foaf:name":[{"@value":"Nozomi Niitsu"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994554110469","@type":"Researcher","foaf:name":[{"@value":"Junko Okabe-Kado"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1410001204872938889","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000258055485"},{"@type":"NRID","@value":"9000411239272"},{"@type":"NRID","@value":"9000000480762"},{"@type":"NRID","@value":"9000240538447"},{"@type":"NRID","@value":"9000021938019"},{"@type":"NRID","@value":"9000016391849"},{"@type":"NRID","@value":"9000403710853"},{"@type":"NRID","@value":"9000018194123"},{"@type":"NRID","@value":"9000001153002"},{"@type":"NRID","@value":"9000290130064"},{"@type":"NRID","@value":"9000021493584"},{"@type":"NRID","@value":"9000021835411"},{"@type":"NRID","@value":"9000345287426"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/MNrd847123"}],"foaf:name":[{"@value":"Masataka Okamoto"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994554110470","@type":"Researcher","foaf:name":[{"@value":"Toshiyuki Takagi"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994554110466","@type":"Researcher","foaf:name":[{"@value":"Takashi Yoshida"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326231372032","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"40242408"},{"@type":"NRID","@value":"1000040242408"},{"@type":"NRID","@value":"9000003906485"},{"@type":"NRID","@value":"9000398152527"},{"@type":"NRID","@value":"9000258033762"},{"@type":"NRID","@value":"9000241460790"},{"@type":"NRID","@value":"9000404952730"},{"@type":"NRID","@value":"9000404952766"},{"@type":"NRID","@value":"9000016770491"},{"@type":"NRID","@value":"9000410499416"},{"@type":"NRID","@value":"9000404952743"},{"@type":"NRID","@value":"9000410874026"},{"@type":"NRID","@value":"9000020573879"},{"@type":"NRID","@value":"9000405037461"},{"@type":"NRID","@value":"9000242741928"},{"@type":"NRID","@value":"9000411022976"},{"@type":"NRID","@value":"9000261677705"},{"@type":"NRID","@value":"9000001488620"},{"@type":"NRID","@value":"9000256895266"},{"@type":"NRID","@value":"9000021429453"},{"@type":"NRID","@value":"9000411023219"},{"@type":"NRID","@value":"9000018556084"},{"@type":"NRID","@value":"9000241860417"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/2159"}],"foaf:name":[{"@value":"Sadao Aoki"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994554110468","@type":"Researcher","foaf:name":[{"@value":"Masami Hirano"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994554110465","@type":"Researcher","foaf:name":[{"@value":"Yoshio Honma"}],"jpcoar:affiliationName":[{"@value":"From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan."}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"15280020"},{"@type":"PISSN","@value":"00064971"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"2001-03-01","prism:volume":"97","prism:number":"5","prism:startingPage":"1202","prism:endingPage":"1210"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/97/5/1202/1671769/1202.pdf"}],"createdAt":"2002-07-27","modifiedAt":"2024-12-09","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Adolescent","dc:title":"Adolescent"},{"@id":"https://cir.nii.ac.jp/all?q=Actuarial%20Analysis","dc:title":"Actuarial Analysis"},{"@id":"https://cir.nii.ac.jp/all?q=Antigens,%20Neoplasm","dc:title":"Antigens, Neoplasm"},{"@id":"https://cir.nii.ac.jp/all?q=Freezing","dc:title":"Freezing"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Monomeric%20GTP-Binding%20Proteins","dc:title":"Monomeric GTP-Binding Proteins"},{"@id":"https://cir.nii.ac.jp/all?q=Aged,%2080%20and%20over","dc:title":"Aged, 80 and over"},{"@id":"https://cir.nii.ac.jp/all?q=Lymphoma,%20Non-Hodgkin","dc:title":"Lymphoma, Non-Hodgkin"},{"@id":"https://cir.nii.ac.jp/all?q=Receptors,%20Interleukin-2","dc:title":"Receptors, Interleukin-2"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=NM23%20Nucleoside%20Diphosphate%20Kinases","dc:title":"NM23 Nucleoside Diphosphate Kinases"},{"@id":"https://cir.nii.ac.jp/all?q=Prognosis","dc:title":"Prognosis"},{"@id":"https://cir.nii.ac.jp/all?q=Survival%20Rate","dc:title":"Survival Rate"},{"@id":"https://cir.nii.ac.jp/all?q=Hyaluronan%20Receptors","dc:title":"Hyaluronan Receptors"},{"@id":"https://cir.nii.ac.jp/all?q=Nucleoside-Diphosphate%20Kinase","dc:title":"Nucleoside-Diphosphate Kinase"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Biomarkers","dc:title":"Biomarkers"},{"@id":"https://cir.nii.ac.jp/all?q=Follow-Up%20Studies","dc:title":"Follow-Up Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Transcription%20Factors","dc:title":"Transcription Factors"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232348216832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"NM23 downregulation and lysophosphatidic acid receptor EDG2/lpa1 upregulation during myeloid differentiation of human leukemia cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235508006912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with the R‐<scp>CHOP</scp> regimen"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693644273536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185660882688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum concentration of <scp>L</scp>‐kynurenine predicts the clinical outcome of patients with diffuse large B‐cell lymphoma treated with R‐CHOP"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656130350720","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205031736960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"生物学的予後因子の臨床的意義"},{"@value":"生物学的予後因子の臨床的意義--血清および細胞表面nm23-H1蛋白の検討を中心に"},{"@language":"ja-Kana","@value":"セイブツガクテキ ヨゴ インシ ノ リンショウテキ イギ ケッセイ オヨビ サイボウ ヒョウメン nm23 H1 タンパク ノ ケントウ オ チュウシン ニ"},{"@language":"en","@value":"[Clinical significance of biological prognostic factors in non-Hodgkin lymphoma: analysis of serum and cell surface nm 23-H1 protein]."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205032238720","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"非Hodgkinリンパ腫における血清nm23-H1蛋白の予後因子としての臨床的意義"},{"@value":"第42回日本臨床血液学会総会 特別賞受賞論文 非Hodgkinリンパ腫における血清nm23-H1蛋白の予後因子としての臨床的意義"},{"@language":"ja-Kana","@value":"ダイ42カイ ニホン リンショウ ケツエキ ガッカイ ソウカイ トクベツショウ ジュショウ ロンブン ヒHodgkin リンパ シュ ニ オケル ケッセイ nm23 H1 タンパク ノ ヨゴ インシ ト シテ ノ リンショウテキ イギ"},{"@language":"en","@value":"[Serum levels of mm23-H1 protein and their clinical implications in malignant lymphoma]."}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679681613440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Prognostic Importance of the Soluble Form of IL-2 Receptorα (sIL-2Rα) and its Relationship with Surface Expression of IL-2Rα (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases"},{"@value":"Prognostic Importance of the Soluble Form of IL-2 Receptor^|^alpha; (sIL-2R^|^alpha;) and its Relationship with Surface Expression of IL-2R^|^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679682402176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Association of nm23-H1 Expression with a Poor Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified"}]},{"@id":"https://cir.nii.ac.jp/crid/1520853834479699072","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"疾患予後予測マーカー 造血器疾患の予後因子としてのIndoleamine 2,3-dioxygenase (IDO)"},{"@language":"ja-Kana","@value":"シッカン ヨゴ ヨソク マーカー ゾウケツキ シッカン ノ ヨゴ インシ ト シテ ノ Indoleamine 2,3-dioxygenase (IDO)"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854176210442496","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Extracellular NM23 protein promotes the growth and survival of primary cultured human acute myelogenous leukemia cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600346422912","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950399951939712","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical significance of serum NM23-H1 protein in neuroblastoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood.v97.5.1202"},{"@type":"CIA","@value":"30022492925"},{"@type":"OPENAIRE","@value":"doi_dedup___::31933878f929df6f8bb802a341d7bc60"},{"@type":"CROSSREF","@value":"10.1111/ejh.12139_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"},{"@type":"CROSSREF","@value":"10.1016/j.leukres.2018.01.003_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"},{"@type":"CROSSREF","@value":"10.1155/2012/879368_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"},{"@type":"CROSSREF","@value":"10.3960/jslrt.54.171_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"},{"@type":"CROSSREF","@value":"10.1111/j.1600-0609.2009.01393.x_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"},{"@type":"CROSSREF","@value":"10.3960/jslrt.53.197_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"},{"@type":"CROSSREF","@value":"10.1007/s00277-011-1363-4_references_DOI_2Tnb9DWC9PNmKIdsoUryBETXywV"}]}